IP Library Granted Patent US 7,425,571
Granted Patent B2
US 7,425,571 · App. 10/830,071 · Granted Sep 16, 2008

Method for treating obesity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,425,571
App. No.
10/830,071
Granted
Sep 16, 2008
Kind
B2
Abstract

The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims (28)

1. A method of reducing the weight of an overweight subject, said method comprising: identifying an overweight subject and administering to said overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof, in an amount effective to reduce the weight of said subject.

2. The method according to claim 1 , wherein said effective amount of zonisamide is in the range of about 50 to about 1000 mg/day.

3. The method according to claim 2 , wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

4. The method according to claim 1 , wherein said overweight subject is an obese subject.

5. The method according to claim 1 wherein said pharmaceutical compositions is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

6. The method according to claim 5 , wherein said pharmaceutical composition is administered orally to said subject.

7. The method according to claim 1 , wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

8. The method according to claim 7 , wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

9. The method according to claim 7 , wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

10. A method of reducing weight in an overweight subject, said method comprising: identifying an overweight subject and administering to said overweight subject a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof, in an amount effective to induce weight loss in said subject, wherein the weight loss is ≧5%, or wherein said weight loss continues during the period of administration of said composition comprising zonisamide or a pharmaceutically acceptable salt thereof.

11. The method according to claim 10 , wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

12. The method according to claim 10 , wherein said effective amount of zonisamide is in the range of about 100 to about 600 mg/day.

13. The method according to claim 10 , wherein said overweight subject is an obese subject.

14. The method according to claim 10 , wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

15. The method according to claim 14 , wherein said pharmaceutical composition is administered orally to said subject.

16. The method according to claim 10 , wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

17. The method according to claim 16 , wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

18. The method according to claim 17 , wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

19. A method of treating obesity by reducing the weight of an obese subject, said method comprising: identifying an obese subject and administering to said obese subject an effective amount of a pharmaceutical composition comprising zonisamide, or a pharmaceutically acceptable salt thereof.

20. The method according to claim 19 , wherein said effective amount of zonisamide is in the range of about 50 to about 100 mg/day.

21. The method according to claim 19 , wherein said effective amount of zonisamide is in the range of about 100 about 600 mg/day.

22. The method according to claim 19 , wherein said obese subject has a BMI of at least 30 kg/m 2 .

23. The method according to claim 19 , wherein said pharmaceutical composition is administered by a route selected from the group consisting of oral, parenteral, topical, injection and rectal administration.

24. The method according to claim 23 , wherein said pharmaceutical composition is administered orally to said subject.

25. The method according to claim 19 , wherein said pharmaceutical composition is administered in combination with another therapeutic method commonly used to reduce weight.

26. The method according to claim 25 , wherein said pharmaceutical composition is administered in combination with a reduced calorie diet or increased physical activity.

27. The method according to claim 26 , wherein said pharmaceutical composition is administered in combination with orlistat, phentermine, sibutramine, topiramate, or sibutramine hydrochloride.

28. A method of treating obesity by reducing the weight of an obese subject, said method comprising: identifying an obese subject and orally administering to said obese subject a capsule comprising a pharmaceutical composition comprising zonisamide or a pharmaceutically acceptable salt thereof, wherein said subject receives a daily dose of 100 to 600 mg of zonisamide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2007
From: GADDE, KISHORE M.; KRISHNAN, K. RANGA R.
To: DUKE UNIVERSITY
Reel/Frame 019082/0949 →